Aprepitant and Fosaprepitant | 合法藥品大搜索

商品名, emend 80mg（低劑量）, 藥品許可證, 衛署藥輸字第023985號 ... Neurokinin-1 receptor antagonist （如aprepitant、fosaprepitant）(94/10/1、101/​02/1、 ... Read More

由 Z Zhang 著作 · 2020 · 被引用 1 次 — Fosaprepitant is a phosphorylated analog of aprepitant with excellent water-​solubility, enabling it rapidly convert to aprepitant after intravenous injection (6). Two ... Read More

由 P Langford 著作 · 2010 · 被引用 31 次 — Fosaprepitant is a recently approved intravenous prodrug of aprepitant that has been shown to be bioequivalent. As an intravenous formulation, ... Read More

由 M Aapro 著作 · 2015 · 被引用 104 次 — Aprepitant (and its prodrug fosaprepitant) is a neurokinin-1 receptor antagonist approved more than a decade ago for the prevention of chemotherapy-induced ... Read More

由 P Patel 著作 · 2017 · 被引用 48 次 — Aprepitant and fosaprepitant, commonly used for the prevention of chemotherapy​‐induced nausea and vomiting, alter cytochrome P450 activity. This systematic ... Read More

由 P Langford 著作 · 2010 · 被引用 31 次 — Fosaprepitant and aprepitant are recommended in guidelines for preventing CINV due to moderately and highly emetogenic chemotherapy. Read More

由 M Aapro 著作 · 2015 · 被引用 104 次 — Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse ... Read More

由 P Patel 著作 · 2017 · 被引用 48 次 — The potential for a drug interaction with aprepitant and fosaprepitant should be considered when selecting antiemetic therapy. Read More

對嚴重腎功能不全患者以及需洗腎的末期腎病(ESRD)患者均不須調整EMEND 的劑量。 藥效學(Pharmacodynamics). Fosaprepitant (aprepitant 的前驅藥)在靜脈輸注 ... Read More

Fosaprepitant, a water-soluble phosphoryl prodrug for aprepitant, is converted to aprepitant via phosphatases following intravenous administration. Given the rapid ... Read More